F

Fluoguide AS
STO:FLUO

Watchlist Manager
Fluoguide AS
STO:FLUO
Watchlist
Price: 33.9 SEK -0.44% Market Closed
Market Cap: 461.7m SEK
Have any thoughts about
Fluoguide AS?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-6.1
Current
-12.8
Median
4.3
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-6.1
=
Enterprise Value
375.7m SEK
/
EBITDA
-39.8m DKK
All Countries
Close
Market Cap EV/EBITDA
DK
Fluoguide AS
STO:FLUO
420.7m SEK -6.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -216 796.7
US
Abbvie Inc
NYSE:ABBV
301B USD 14.8
US
Amgen Inc
NASDAQ:AMGN
162B USD 17.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.5B USD 26.9
US
Gilead Sciences Inc
NASDAQ:GILD
115.4B USD 10.2
US
Epizyme Inc
F:EPE
94.1B EUR -521.2
AU
CSL Ltd
ASX:CSL
138B AUD 20.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.6B USD 17.5
US
Seagen Inc
F:SGT
39.3B EUR -59.5
NL
argenx SE
XBRU:ARGX
34.1B EUR -104.5
EBITDA Growth
DK
F
Fluoguide AS
STO:FLUO
Average EV/EBITDA: 18
Negative Multiple: -6.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.8
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.9
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.9
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-4.2
2-Years Forward
EV/EBITDA
-2.9
3-Years Forward
EV/EBITDA
5.5

See Also

Discover More